Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GILD Stock Forecast 2025-2026
$106.74
Current Price
$133.77B
Market Cap
Buy 19
Hold 11
Sell 0
Wall St Analyst Ratings
Distance to GILD Price Targets
+31.2%
To High Target of $140.00
+8.7%
To Median Target of $116.00
-13.8%
To Low Target of $92.00
GILD Price Momentum
+4.1%
1 Week Change
+0.3%
1 Month Change
+61.3%
1 Year Change
+15.6%
Year-to-Date Change
-11.0%
From 52W High of $119.96
+72.0%
From 52W Low of $62.07
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Gilead (GILD) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on GILD and similar high-potential opportunities.
Latest GILD Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, GILD has a bullish consensus with a median price target of $116.00 (ranging from $92.00 to $140.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $106.74, the median forecast implies a 8.7% upside. This outlook is supported by 19 Buy, 11 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mohit Bansal at Wells Fargo, projecting a 31.2% upside. Conversely, the most conservative target is provided by Jason McCarthy at Maxim Group, suggesting a 13.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GILD Analyst Ratings
19
Buy
11
Hold
0
Sell
GILD Price Target Range
Low
$92.00
Average
$116.00
High
$140.00
Current: $106.74
Latest GILD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GILD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| May 5, 2025 | Mizuho | Outperform | Maintains | $0.00 | |
| Apr 25, 2025 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $125.00 |
| Apr 25, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Apr 25, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $135.00 |
| Apr 22, 2025 | Cantor Fitzgerald | Carter Gould | Overweight | Assumes | $125.00 |
| Apr 17, 2025 | BMO Capital | Outperform | Maintains | $0.00 | |
| Mar 27, 2025 | JP Morgan | Chris Schott | Overweight | Maintains | $130.00 |
| Mar 11, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $130.00 |
| Mar 5, 2025 | B of A Securities | Tim Anderson | Buy | Maintains | $126.00 |
| Mar 5, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $140.00 |
| Mar 4, 2025 | Oppenheimer | Hartaj Singh | Outperform | Maintains | $132.00 |
| Feb 18, 2025 | Deutsche Bank | James Shin | Buy | Upgrade | $120.00 |
| Feb 13, 2025 | B of A Securities | Buy | Maintains | $0.00 | |
| Feb 12, 2025 | Baird | Neutral | Maintains | $0.00 | |
| Feb 12, 2025 | BMO Capital | Evan Seigerman | Outperform | Maintains | $115.00 |
| Feb 12, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $120.00 |
| Feb 12, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $0.00 |
| Feb 12, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $90.00 |
| Feb 12, 2025 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $96.00 |
Gilead Sciences Inc. (GILD) Competitors
The following stocks are similar to Gilead based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Gilead Sciences Inc. (GILD) Financial Data
Gilead Sciences Inc. has a market capitalization of $133.77B with a P/E ratio of 22.6x. The company generates $28.74B in trailing twelve-month revenue with a 20.8% profit margin.
Revenue growth is -0.3% quarter-over-quarter, while maintaining an operating margin of +38.5% and return on equity of +32.7%.
Valuation Metrics
Market Cap
$133.77B
Enterprise Value
$150.15B
P/E Ratio
22.6x
PEG Ratio
14.5x
Price/Sales
4.7x
Growth & Margins
Revenue Growth (YoY)
-0.3%
Gross Margin
+76.9%
Operating Margin
+38.5%
Net Margin
+20.8%
EPS Growth
-0.3%
Financial Health
Cash/Price Ratio
+6.6%
Current Ratio
1.4x
Debt/Equity
130.8x
ROE
+32.7%
ROA
+12.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Gilead Sciences Inc. (GILD) Business Model
About Gilead Sciences Inc.
What They Do
Develops innovative biopharmaceutical medicines.
Business Model
Gilead Sciences generates revenue by researching, developing, and commercializing medicines that address unmet medical needs, particularly in HIV, liver diseases, and cancer. The company earns income through the sale of its established antiviral therapies and anticipates future revenue from a strong pipeline of investigational drugs.
Additional Information
Headquartered in Foster City, California, Gilead is recognized for its significant contributions to healthcare and patient longevity. The company actively engages in strategic partnerships to enhance its innovative capabilities and maintain its competitive edge in the global pharmaceutical market.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,600
CEO
Mr. Daniel P. O'Day
Country
United States
IPO Year
1992
Website
www.gilead.comGilead Sciences Inc. (GILD) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
May 21, 2025
By Zacks Equity Research
Tale of the Tape
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide portfolio, upcoming product launches, promising pipeline candidates and recent positive estimate revisions
May 20, 2025
By Ekta Bagri
Analyst Blog
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
May 20, 2025
By Zacks Equity Research
Smart Beta ETF
Latest News
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
2 days ago
Quick Summary
Gilead Sciences' Executive VP, Cindy Perettie, will represent the company at the RBC Capital Markets Global Healthcare Conference on May 21, 2025, discussing their CAR-T franchise.
Why It Matters
Gilead's participation in the RBC Capital Markets Conference highlights its CAR-T franchise leadership, signaling potential growth and innovation in oncology, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Zacks Style Scores help investors identify top-rated stocks tailored to their investing style, providing a streamlined approach to stock selection.
Why It Matters
Zacks Style Scores provide a systematic approach to identify high-potential stocks, enhancing investment strategies and potentially improving returns.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Gilead Sciences (GILD) and GSK are leaders in HIV treatment development, highlighting their significant roles in the healthcare sector.
Why It Matters
Gilead and GSK's leadership in HIV treatment indicates strong market positioning, potential for growth, and innovation, which could affect stock performance and investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
The S&P 500 is experiencing volatility following two strong years of stock performance.
Why It Matters
The S&P 500's recent turbulence signals potential volatility ahead, which may affect investor confidence and market strategies after strong gains in previous years.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Zacks.com users are closely monitoring Gilead (GILD), indicating potential investor interest and warranting further examination of the stock's prospects.
Why It Matters
Increased interest in Gilead (GILD) from Zacks.com users may indicate potential stock volatility or investment opportunities, prompting investors to assess the company's prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Gilead Sciences will present over 20 research abstracts at the ASCO Annual Meeting (May 30 - June 3, 2025) and EHA Congress (June 12 - 15, 2025), covering various cancers.
Why It Matters
Gilead's presentation of over 20 abstracts at major oncology conferences signals potential advancements in cancer treatment, influencing investor sentiment and stock performance in biotech.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About GILD Stock
What is Gilead Sciences Inc.'s (GILD) stock forecast for 2025?
Based on our analysis of 36 Wall Street analysts, Gilead Sciences Inc. (GILD) has a median price target of $116.00. The highest price target is $140.00 and the lowest is $92.00.
Is GILD stock a good investment in 2025?
According to current analyst ratings, GILD has 19 Buy ratings, 11 Hold ratings, and 0 Sell ratings. The stock is currently trading at $106.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GILD stock?
Wall Street analysts predict GILD stock could reach $116.00 in the next 12 months. This represents a 8.7% increase from the current price of $106.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Gilead Sciences Inc.'s business model?
Gilead Sciences generates revenue by researching, developing, and commercializing medicines that address unmet medical needs, particularly in HIV, liver diseases, and cancer. The company earns income through the sale of its established antiviral therapies and anticipates future revenue from a strong pipeline of investigational drugs.
What is the highest forecasted price for GILD Gilead Sciences Inc.?
The highest price target for GILD is $140.00 from Mohit Bansal at Wells Fargo, which represents a 31.2% increase from the current price of $106.74.
What is the lowest forecasted price for GILD Gilead Sciences Inc.?
The lowest price target for GILD is $92.00 from Jason McCarthy at Maxim Group, which represents a -13.8% decrease from the current price of $106.74.
What is the overall GILD consensus from analysts for Gilead Sciences Inc.?
The overall analyst consensus for GILD is bullish. Out of 36 Wall Street analysts, 19 rate it as Buy, 11 as Hold, and 0 as Sell, with a median price target of $116.00.
How accurate are GILD stock price projections?
Stock price projections, including those for Gilead Sciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:15 PM UTC